Evidence map›Paper›PMID 36140756›Full record

ArticleGenes2022

Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations.

Midie Xu, Jiuliang Yan, Beiyuan Hu, Chuntao Wu, Haitao Gu, Zihao Qi, Tao Chen, Wenting Yang, Yan Zheng, Hanguang Dong and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06592989 (A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of Pancreatic Neuroendocrine Tumor Patients Who Have Progressed After Previous Treatment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06592989 recruitingnot on this mapstarted 2024, after this paper: background citation

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of Pancreatic Neuroendocrine Tumor Patients Who Have Progressed After Previous Treatment

TypeobservationalSponsorShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRan2024 to 2026Enrolled20ConditionsPancreatic Neuroendocrine Neoplasm, Sorafenib, GefitinibArmssorafenib, gefitinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0003-1775-6608
Jiuliang YanDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Beiyuan HuDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Chuntao WuDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Haitao GuDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Zihao QiDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Tao ChenDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Wenting YangDepartment of Genetics, Stanford University, Stanford, CA 94305, USA.
Yan ZhengDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Hanguang DongDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jiang LongDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Shanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CNStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver metastases are common in pancreatic neuroendocrine tumors (PanNETs) patients and they are considered a poor prognostic marker. This study aims to analyze the spatiotemporal patterns of genomic variations between primary and metastatic tumors, and to identify the key related biomolecular pathways. We performed next-generation sequencing on paired tissue specimens of primary PanNETs (

Indexed as

Liver NeoplasmsNeoplasms, Second PrimaryNeuroendocrine TumorsPancreatic NeoplasmsDNA Copy Number VariationsGenomicsHumansDNA repairgenomic heterogeneityliver metastasispancreatic neuroendocrine tumorstyrosine kinase

Identifiers

PMID36140756
PMCPMC9498575
OpenAlexW4294794397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.